Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)()

First-line therapy for higher-risk myelodysplastic syndromes (MDS) includes decitabine (DAC) or azacitidine (AZA). Variables have not identified differential response rates between these. We assessed the influence of patient sex on outcomes including overall survival (OS) in 642 patients with higher...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: DeZern, Amy E., Zeidan, Amer M., Barnard, John, Hand, Wesley, Al Ali, Najla, Brown, Francis, Zimmerman, Cassie, Roboz, Gail J., Garcia-Manero, Guillermo, Steensma, David P., Komrokji, Rami S., Sekeres, Mikkael A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5394924/
https://ncbi.nlm.nih.gov/pubmed/27774847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1246726
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados